Lataa...
Current treatment of atypical hemolytic uremic syndrome
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically,...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4204535/ https://ncbi.nlm.nih.gov/pubmed/25343125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2014.01001 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|